ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.Gut · 2024
   Article
2. Survival outcomes of surgical and non-surgical treatment in elderly patients with stage I pancreatic cancer: A population-based analysis.Frontiers in medicine · 2022
   Article
3. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer.Cancer research · 2021
   Article
4. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival.BMC cancer · 2019
   Article
5. Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail.Journal of gastrointestinal oncology · 2018
   Article
6. A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2016
   Article
7. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.Journal of gastrointestinal cancer · 2015
   Article
8. Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma.Seminars in oncology · 2015
   Review
9. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial.Annals of surgical oncology · 2011
   Article
10. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.Annals of surgical oncology · 2010
    Article
11. Current status of adjuvant therapy for pancreatic cancer.The oncologist · 2010
    Article
12. Diagnosis and management of pancreatic cancer.Minerva gastroenterologica e dietologica · 2009
    Review
13. Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal".Drugs · 2007
    Review
14. Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins.Advances in radiation oncology
    Article

Corrections and comments

• Comment on
  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.2001
• Comment on
  Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.2001

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as